These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24433088)

  • 21. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
    J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
    Alegre A; Gironella M; Bailén A; Giraldo P
    Eur J Haematol; 2014 Mar; 92(3):181-8. PubMed ID: 24330023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
    Kleber M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2019 Aug; 12(8):651-663. PubMed ID: 31268745
    [No Abstract]   [Full Text] [Related]  

  • 26. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and treatment of myeloma bone disease.
    Terpos E; Kastritis E; Dimopoulos MA
    Curr Hematol Malig Rep; 2012 Dec; 7(4):249-57. PubMed ID: 22941027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment for myeloma bone disease.
    Yeh HS; Berenson JR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the biology and treatment of bone disease in multiple myeloma.
    Raje N; Roodman GD
    Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates in multiple myeloma.
    Berenson JR
    Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials of bisphosphonates in multiple myeloma.
    Mahindra A; Pozzi S; Raje N
    Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of multiple myeloma bone disease: experimental and clinical data.
    Papamerkouriou YM; Kenanidis E; Gamie Z; Papavasiliou K; Kostakos T; Potoupnis M; Sarris I; Tsiridis E; Kyrkos J
    Expert Opin Biol Ther; 2015 Feb; 15(2):213-30. PubMed ID: 25388648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of painful bone lesions and hypercalcemia.
    Ascari E; Attardo-Parrinello G; Merlini G
    Eur J Haematol Suppl; 1989; 51():135-9. PubMed ID: 2534078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.